What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing

Our understanding of bone and soft tissue tumors has thoroughly evolved as a consequence of modern molecular techniques. DNA and RNA sequencing methods play an important diagnostic and therapeutic role in sarcoma pathology. Herein, we discuss current guidelines and best practices for molecular testi...

Descripción completa

Detalles Bibliográficos
Autor principal: Obeidin, Farres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2023
Materias:
Newsletter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209662/
https://www.ncbi.nlm.nih.gov/pubmed/37015324
http://dx.doi.org/10.4132/jptm.2023.03.20
_version_ 1785046924633571328
author Obeidin, Farres
author_facet Obeidin, Farres
author_sort Obeidin, Farres
collection PubMed
description Our understanding of bone and soft tissue tumors has thoroughly evolved as a consequence of modern molecular techniques. DNA and RNA sequencing methods play an important diagnostic and therapeutic role in sarcoma pathology. Herein, we discuss current guidelines and best practices for molecular testing in bone and soft tissue tumors.
format Online
Article
Text
id pubmed-10209662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-102096622023-05-26 What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing Obeidin, Farres J Pathol Transl Med Newsletter Our understanding of bone and soft tissue tumors has thoroughly evolved as a consequence of modern molecular techniques. DNA and RNA sequencing methods play an important diagnostic and therapeutic role in sarcoma pathology. Herein, we discuss current guidelines and best practices for molecular testing in bone and soft tissue tumors. The Korean Society of Pathologists and the Korean Society for Cytopathology 2023-05 2023-04-05 /pmc/articles/PMC10209662/ /pubmed/37015324 http://dx.doi.org/10.4132/jptm.2023.03.20 Text en © The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Newsletter
Obeidin, Farres
What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title_full What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title_fullStr What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title_full_unstemmed What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title_short What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
title_sort what’s new in bone and soft tissue pathology 2023: guidelines for molecular testing
topic Newsletter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209662/
https://www.ncbi.nlm.nih.gov/pubmed/37015324
http://dx.doi.org/10.4132/jptm.2023.03.20
work_keys_str_mv AT obeidinfarres whatsnewinboneandsofttissuepathology2023guidelinesformoleculartesting

Ejemplares similares